Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol
Public ClinicalTrials.gov record NCT04746989. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines- Probenecid vs Allopurinol
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Study identification
- NCT ID
- NCT04746989
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 294,878 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2021
- Primary completion
- Jul 16, 2023
- Completion
- Dec 30, 2023
- Last update posted
- Feb 26, 2026
2021 – 2023
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Brigham and Women's Hospital | Boston | Massachusetts | 02120 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Gout trials
Other public records listing Gout. Sorted by last update posted; newest first. Not a recommendation.
- NCT07535034: A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants Recruiting
- NCT07116746: Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients Active, not recruiting
- NCT07089875: A Study of Dotinurad Versus Allopurinol in Participants With Gout Recruiting
- NCT06846515: Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301) Active, not recruiting
- NCT04075903: Gout in the ED and Improving Research Participation Active, not recruiting
- NCT07367971: Drug-Drug Interaction Study of ABP-671 in Gout Patients Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04746989, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 26, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04746989 live on ClinicalTrials.gov.